Australia markets close in 2 hours 34 minutes
  • ALL ORDS

    7,067.80
    +25.10 (+0.36%)
     
  • ASX 200

    6,813.20
    +23.60 (+0.35%)
     
  • AUD/USD

    0.7755
    -0.0022 (-0.28%)
     
  • OIL

    59.79
    -0.85 (-1.40%)
     
  • GOLD

    1,712.70
    -10.30 (-0.60%)
     
  • BTC-AUD

    63,608.34
    +3,804.37 (+6.36%)
     
  • CMC Crypto 200

    986.66
    +58.43 (+6.29%)
     
  • AUD/EUR

    0.6442
    -0.0008 (-0.12%)
     
  • AUD/NZD

    1.0688
    -0.0003 (-0.03%)
     
  • NZX 50

    12,402.47
    +100.66 (+0.82%)
     
  • NASDAQ

    13,282.95
    +373.51 (+2.89%)
     
  • FTSE

    6,588.53
    +105.10 (+1.62%)
     
  • Dow Jones

    31,535.51
    +603.14 (+1.95%)
     
  • DAX

    14,012.82
    +226.53 (+1.64%)
     
  • Hang Seng

    29,694.90
    +242.33 (+0.82%)
     
  • NIKKEI 225

    29,582.39
    -81.11 (-0.27%)
     

Biorasi Welcomes Neurology Professor Dr. Ole Isacson to Scientific Advisory Board

·2-min read

Biorasi, a leading global full-service contract research organization (CRO), is proud to announce the appointment of Ole Isacson, MD, PhD, Professor of Neurology and Neuroscience, to the position of Scientific Advisory Board (SAB) member. In this role, Dr. Isacson will provide leadership and clinical expertise for neurology clinical trials and related areas at Biorasi.

"I look forward to working with Dr. Isacson in expanding our knowledge base in neurology, including rare and urgent diseases," said Jimmy El Hokayem, PhD, Head of the Neurology and Regenerative Medicine Center of Excellence and Associate Director of Program Development at Biorasi. "I genuinely believe that his unique profile as one of today’s prominent clinical leaders and eminent researchers will drive neurology clinical trials forward for 2021 and beyond."

Dr. Isacson is one of four SAB members that will be joining Biorasi in 2021. This esteemed group of clinicians and researchers will include experts in the fields of dermatology, nephrology, neurology, and oncology, working together with Biorasi’s Board of Directors and company leadership.

Dr. Isacson is a Professor of Neurology and Neuroscience at Harvard Medical School and Founding Director of the Neuroregeneration Institute at McLean Hospital. In this role, he is at the forefront of research into neurodegenerative disease and regenerative medicine for brain disorders. He has served as Executive Scientific Advisory Board Member for the Michael J. Fox Foundation and held memberships in the International Parkinson and Movement Society and the FDA’s Cellular, Tissues, and Gene Therapies Advisory Committee.

He received his MD and PhD in Medical Neurobiology from the University of Lund in Sweden, completed his research fellowship in Neuroscience at the University of Cambridge, and holds honorary degrees from both Harvard University and University of Lund.

"I am very much looking forward to working with Biorasi," said Dr. Isacson. "In my new role, I look forward to adding my expertise and collaborating with other SAB members to promote growth and innovation in clinical research."

About Biorasi

Biorasi is a customer-focused, full-service, contract research organization (CRO) that leverages speed and agility in the execution of clinical trials to maximize speed-to-market for its sponsors. Biorasi is a leader in dermatology, neurology, nephrology, oncology, and the emerging digital therapeutics market. To learn more, contact Biorasi at info@biorasi.com / (786) 388-0700.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210126005726/en/

Contacts

Adam Gottlieb (954) 410-3654 agottlieb@biorasi.com